Publications

Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
Transplantation and cellular therapy. 2024 Mar 16; Authors: Chong EA, Chong ER, Therwhangher D, Nasta SD, Landsburg DJ, Barta SK, Svoboda J, Gerson JN, Ghilardi G, Paruzzo L, Fraietta JA, Weber E, Stefano N, Porter DL, Frey NV, Garfall AL, Ruella M, Schuster SJ

Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
The Journal of infectious diseases. 2024 Mar 4; Authors: Chong EA, Kumashie KG, Chong ER, Fabrizio J, Gupta A, Svoboda J, Barta SK, Walsh KM, Napier EB, Lundberg RK, Nasta SD, Gerson JN, Landsburg DJ, Gonzalez J, Gaano A, Weirick ME, McAllister CM, Awofolaju M, John GN, Kammerman SC, Novaceck J, Pajarillo R, Lundgreen KA, Tanenbaum N, Gouma S, Drapeau EM, Adamski S, D'Andrea K, Pattekar A, Hicks A, Korte S, Sharma H, Herring S, Williams JC, Hamilton JT, Bates P, Hensley SE, Prak ETL, Greenplate AR, Wherry EJ, Schuster SJ, Ruella M, Vella LA

Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing.
Cytotherapy. 2024 Feb 16; Authors: Pajarillo R, Paruzzo L, Carturan A, Ugwuanyi O, White G, Guruprasad P, Ballard HJ, Patel RP, Zhang Y, Lee YG, Hong SJA, Dittami GM, Ruella M

Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines.
Blood advances. 2024 Feb 13;8(3):653-666; Authors: Ghilardi G, Paruzzo L, Svoboda J, Chong EA, Shestov AA, Chen L, Cohen IJ, Gabrielli G, Nasta SD, Porazzi P, Landsburg DJ, Gerson JN, Carter J, Barta SK, Yelton R, Pajarillo R, Patel V, White G, Ballard HJ, Weber E, Napier E, Chong ER, Fraietta JA, Garfall AL, Porter DL, Milone MC, O'Connor R, Schuster SJ, Ruella M

Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.
Transplantation and cellular therapy. 2024 Feb;30(2):171-186 Epub 2023 Oct 21; Authors: Angelos MG, Patel RP, Ruella M, Barta SK

T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Nature medicine. 2024 Jan 24; Authors: Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, Paruzzo L, Harris JC, Chong EA, Susanibar Adaniya SP, Svoboda J, Nasta SD, Ugwuanyi OH, Landsburg DJ, Fardella E, Waxman AJ, Chong ER, Patel V, Pajarillo R, Kulikovskaya I, Lieberman DB, Cohen AD, Levine BL, Stadtmauer EA, Frey NV, Vogl DT, Hexner EO, Barta SK, Porter DL, Garfall AL, Schuster SJ, June CH, Ruella M

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy.
Blood. 2024 Jan 11;143(2):139-151; Authors: Tang Y, Liu W, Kadu S, Johnson O, Hasanali ZS, Kelly A, Shestov A, Pajarillo R, Greenblatt E, Holmes M, Wang LP, Shih N, O'Connor RS, Ruella M, Garfall AL, Allman D, Vogl DT, Cohen A, June CH, Sheppard NC

ALKemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma.
Cancer cell. 2023 Dec 11;41(12):2016-2018; Authors: Ruella M

Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
Molecular cancer. 2023 Dec 9;22(1):200; Authors: Zhang Y, Patel RP, Kim KH, Cho H, Jo JC, Jeong SH, Oh SY, Choi YS, Kim SH, Lee JH, Angelos M, Guruprasad P, Cohen I, Ugwuanyi O, Lee YG, Pajarillo R, Cho JH, Carturan A, Paruzzo L, Ghilardi G, Wang M, Kim S, Kim SM, Lee HJ, Park JH, Cui L, Lee TB, Hwang IS, Lee YH, Lee YJ, Porazzi P, Liu D, Lee Y, Kim JH, Lee JS, Yoon DH, Chung J, Ruella M

Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies.
Nature reviews. Drug discovery. 2023 Dec;22(12):976-995 Epub 2023 Oct 31; Authors: Ruella M, Korell F, Porazzi P, Maus MV

CAR(+) and CAR(-) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies.
Nature communications. 2023 Nov 27;14(1):7767; Authors: Louie RHY, Cai C, Samir J, Singh M, Deveson IW, Ferguson JM, Amos TG, McGuire HM, Gowrishankar K, Adikari T, Balderas R, Bonomi M, Ruella M, Bishop D, Gottlieb D, Blyth E, Micklethwaite K, Luciani F

Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.
Blood. 2023 Nov 16;142(20):1724-1739; Authors: Ang Z, Paruzzo L, Hayer KE, Schmidt C, Torres Diz M, Xu F, Zankharia U, Zhang Y, Soldan S, Zheng S, Falkenstein CD, Loftus JP, Yang SY, Asnani M, King Sainos P, Pillai V, Chong E, Li MM, Tasian SK, Barash Y, Lieberman PM, Ruella M, Schuster SJ, Thomas-Tikhonenko A

Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Nature medicine. 2023 Nov;29(11):2954; Authors: Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M

Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells.
Immunity. 2023 Oct 10;56(10):2388-2407.e9 Epub 2023 Sep 29; Authors: Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, Da T, Gohil M, Chen L, Hong SA, Ravikumar P, Rennels AK, Salas-Mckee J, Kong W, Ruella M, Davis MM, Plesa G, Fraietta JA, Porter DL, Young RM, June CH

DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
Blood. 2023 Sep 14;142(11):973-988; Authors: Zhou N, Choi J, Grothusen G, Kim BJ, Ren D, Cao Z, Liu Y, Li Q, Inamdar A, Beer T, Tang HY, Perkey E, Maillard I, Bonasio R, Shi J, Ruella M, Wan L, Busino L

Harnessing the Gut Microbiota to Potentiate the Efficacy of CAR T Cell Therapy.
HemaSphere. 2023 Sep;7(9):e950 Epub 2023 Aug 23; Authors: Gabrielli G, Shouval R, Ghilardi G, van den Brink M, Ruella M

Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.
bioRxiv : the preprint server for biology. 2023 Aug 16; Authors: Ang Z, Paruzzo L, Hayer KE, Schmidt C, Torres Diz M, Xu F, Zankharia U, Zhang Y, Soldan S, Zheng S, Falkenstein CD, Loftus JP, Yang SY, Asnani M, King Sainos P, Pillai V, Chong E, Li MM, Tasian SK, Barash Y, Lieberman PM, Ruella M, Schuster SJ, Thomas-Tikhonenko A

Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma.
Blood advances. 2023 Jul 25;7(14):3416-3430; Authors: Watanabe K, Gomez AM, Kuramitsu S, Siurala M, Da T, Agarwal S, Song D, Scholler J, Rotolo A, Posey AD, Rook AH, Haun PL, Ruella M, Young RM, June CH

Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies.
Journal for immunotherapy of cancer. 2023 Jun;11(6); Authors: Anderson KG, Braun DA, Buqué A, Gitto SB, Guerriero JL, Horton B, Keenan BP, Kim TS, Overacre-Delgoffe A, Ruella M, Triplett TA, Veeranki O, Verma V, Zhang F

The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022.
Journal of translational medicine. 2023 Apr 22;21(1):275; Authors: Ascierto PA, Brentjens R, Khleif SN, Odunsi K, Rezvani K, Ruella M, Sullivan RJ, Fox BA, Puzanov I

Apoptosis: a Janus bifrons in T-cell immunotherapy.
Journal for immunotherapy of cancer. 2023 Apr;11(4); Authors: Lee YG, Yang N, Chun I, Porazzi P, Carturan A, Paruzzo L, Sauter CT, Guruprasad P, Pajarillo R, Ruella M

Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy.
Molecular therapy : the journal of the American Society of Gene Therapy. 2023 Mar 1;31(3):686-700 Epub 2023 Jan 14; Authors: Uribe-Herranz M, Beghi S, Ruella M, Parvathaneni K, Salaris S, Kostopoulos N, George SS, Pierini S, Krimitza E, Costabile F, Ghilardi G, Amelsberg KV, Lee YG, Pajarillo R, Markmann C, McGettigan-Croce B, Agarwal D, Frey N, Lacey SF, Scholler J, Gabunia K, Wu G, Chong E, Porter DL, June CH, Schuster SJ, Bhoj V, Facciabene A

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia.
Blood advances. 2022 Nov 8;6(21):5774-5785; Authors: Gill S, Vides V, Frey NV, Hexner EO, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon AL, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, Melenhorst JJ, Pequignot E, Ruella M, Shestov M, Byrd JC, Schuster SJ, Siegel DL, Levine BL, June CH, Porter DL

Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
Cancer discovery. 2022 Oct 5;12(10):2372-2391; Authors: Lee YG, Guruprasad P, Ghilardi G, Pajarillo R, Sauter CT, Patel R, Ballard HJ, Hong SJ, Chun I, Yang N, Amelsberg KV, Cummins KD, Svoboda J, Gill S, Chong EA, North K, Church SE, Fraietta JA, Chang WJ, Lacey SF, Lu XM, Zhang Y, Whig K, Schultz DC, Cherry S, Gerson J, Schuster SJ, Porazzi P, Ruella M

Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting.
Clinical lymphoma, myeloma & leukemia. 2022 Aug;22(8):e730-e737 Epub 2022 Apr 20; Authors: Nasta SD, Hughes ME, Namoglu EC, Garfall A, DiFilippo H, Ballard HJ, Barta SK, Chong EA, Frey NV, Gerson JN, Landsburg DJ, Ruella M, Schuster SJ, Svoboda J, Weber E, Porter DL

Antigen glycosylation regulates efficacy of CAR T cells targeting CD19.
Nature communications. 2022 Jun 11;13(1):3367; Authors: Heard A, Landmann JH, Hansen AR, Papadopolou A, Hsu YS, Selli ME, Warrington JM, Lattin J, Chang J, Ha H, Haug-Kroeper M, Doray B, Gill S, Ruella M, Hayer KE, Weitzman MD, Green AM, Fluhrer R, Singh N

Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021.
Journal of translational medicine. 2022 Jun 7;20(1):257; Authors: Ascierto PA, Avallone A, Bhardwaj N, Bifulco C, Bracarda S, Brody JD, Buonaguro L, Demaria S, Emens LA, Ferris RL, Galon J, Khleif SN, Klebanoff CA, Laskowski T, Melero I, Paulos CM, Pignata S, Ruella M, Svane IM, Taube JM, Fox BA, Hwu P, Puzanov I

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Nature medicine. 2022 Apr;28(4):713-723 Epub 2022 Mar 14; Authors: Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M

Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies.
Blood cancer discovery. 2022 Mar 1;3(2):103-115; Authors: Zheng S, Gillespie E, Naqvi AS, Hayer KE, Ang Z, Torres-Diz M, Quesnel-Vallières M, Hottman DA, Bagashev A, Chukinas J, Schmidt C, Asnani M, Shraim R, Taylor DM, Rheingold SR, O'Brien MM, Singh N, Lynch KW, Ruella M, Barash Y, Tasian SK, Thomas-Tikhonenko A

Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
Blood. 2022 Feb 17;139(7):1026-1038; Authors: Chong EA, Alanio C, Svoboda J, Nasta SD, Landsburg DJ, Lacey SF, Ruella M, Bhattacharyya S, Wherry EJ, Schuster SJ

An NK-like CAR T cell transition in CAR T cell dysfunction.
Cell. 2021 Dec 9;184(25):6081-6100.e26 Epub 2021 Dec 2; Authors: Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, Ishiyama K, Wellhausen N, Rennels AK, Ma Y, Tian L, Guedan S, Alexander KA, Zhang Z, Rommel PC, Singh N, Glastad KM, Richardson MW, Watanabe K, Tanyi JL, O'Hara MH, Ruella M, Lacey SF, Moon EK, Schuster SJ, Albelda SM, Lanier LL, Young RM, Berger SL, June CH

(18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma.
Molecular imaging and biology. 2021 Dec;23(6):818-826 Epub 2021 Jul 6; Authors: Ruff A, Ballard HJ, Pantel AR, Namoglu EC, Hughes ME, Nasta SD, Chong EA, Bagg A, Ruella M, Farwell MD, Svoboda J, Sellmyer MA

Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Dec 1;27(23):6298-6306 Epub 2021 Jul 12; Authors: Lemoine J, Ruella M, Houot R

Born to survive: how cancer cells resist CAR T cell therapy.
Journal of hematology & oncology. 2021 Nov 22;14(1):199; Authors: Lemoine J, Ruella M, Houot R

Adoptive T-cell therapy for Hodgkin lymphoma.
Blood advances. 2021 Oct 26;5(20):4291-4302; Authors: Ho C, Ruella M, Levine BL, Svoboda J

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Haematologica. 2021 Jun 1;106(6):1705-1713; Authors: Svoboda J, Bair SM, Landsburg DJ, Dwivedy Nasta S, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ

Immunogenicity of CAR T cells in cancer therapy.
Nature reviews. Clinical oncology. 2021 Jun;18(6):379-393 Epub 2021 Feb 25; Authors: Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, Ruella M, Savoldo B, Shah NN, Turtle CJ, Wayne AS, Abou-El-Enein M

Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts.
Journal for immunotherapy of cancer. 2021 Jun;9(6); Authors: Quintarelli C, Guercio M, Manni S, Boffa I, Sinibaldi M, Di Cecca S, Caruso S, Abbaszadeh Z, Camera A, Cembrola B, Ciccone R, Orfao A, Martin-Martin L, Gutierrez-Herrero S, Herrero-Garcia M, Cazzaniga G, Nunes V, Songia S, Marcatili P, Marin FI, Ruella M, Bertaina V, Vinti L, Del Bufalo F, Algeri M, Merli P, De Angelis B, Locatelli F

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.
Kidney medicine. 2021 Jul-Aug;3(4):665-668 Epub 2021 May 28; Authors: Melilli E, Mussetti A, Linares GS, Ruella M, La Salette C, Savchenko A, Taco MDR, Montero N, Grinyo J, Fava A, Gomà M, Meneghini M, Manonelles A, Cruzado J, Sureda A, Bestard O

CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before.
British journal of haematology. 2021 May;193(3):449-465 Epub 2020 Nov 21; Authors: Ghilardi G, Braendstrup P, Chong EA, Schuster SJ, Svoboda J, Ruella M

Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Nature medicine. 2021 May;27(5):842-850 Epub 2021 Apr 22; Authors: Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, Shyu A, Highfill SL, Price A, Zhao L, Peng L, Granda B, Ramones M, Lu XM, Christian DA, Perazzelli J, Lacey SF, Roy NH, Burkhardt JK, Colomb F, Damra M, Abdel-Mohsen M, Liu T, Liu D, Standley DM, Young RM, Brogdon JL, Grupp SA, June CH, Maude SL, Gill S, Ruella M

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy.
The New England journal of medicine. 2021 Feb 18;384(7):673-674; Authors: Chong EA, Ruella M, Schuster SJ, Lymphoma Program Investigators at the University of Pennsylvania

The current landscape of single-cell transcriptomics for cancer immunotherapy.
The Journal of experimental medicine. 2021 Jan 4;218(1); Authors: Guruprasad P, Lee YG, Kim KH, Ruella M

Human chimeric antigen receptor macrophages for cancer immunotherapy.
Nature biotechnology. 2020 Aug;38(8):947-953 Epub 2020 Mar 23; Authors: Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, Cummins KD, Shen F, Shan X, Veliz K, Blouch K, Yashiro-Ohtani Y, Kenderian SS, Kim MY, O'Connor RS, Wallace SR, Kozlowski MS, Marchione DM, Shestov M, Garcia BA, June CH, Gill S

The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice.
Frontiers in immunology. 2020;11:888 Epub 2020 May 12; Authors: Cerrano M, Ruella M, Perales MA, Vitale C, Faraci DG, Giaccone L, Coscia M, Maloy M, Sanchez-Escamilla M, Elsabah H, Fadul A, Maffini E, Pittari G, Bruno B

Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction.
Cancer discovery. 2020 Apr;10(4):552-567 Epub 2020 Jan 30; Authors: Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ, Mueller KT, Good CR, Berger SL, Shalem O, Weitzman MD, Frey NV, Maude SL, Grupp SA, June CH, Gill S, Ruella M

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells.
Blood. 2020 Feb 13;135(7):505-509; Authors: Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey AD, Hong SJ, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, Gill SI

The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
Cytotherapy. 2020 Feb;22(2):57-69 Epub 2020 Feb 1; Authors: Braendstrup P, Levine BL, Ruella M

Beat pediatric ALL MRD: CD28 CAR T and transplant.
Blood. 2019 Dec 26;134(26):2333-2335; Authors: Ruella M, Locke FL

Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma Cells.
Frontiers in oncology. 2019;9:568 Epub 2019 Jul 3; Authors: Zhang Q, Wang HY, Liu X, Roth MH, Shestov AA, Lee SC, Jain K, Soderquist C, Xiong QB, Ruella M, Strauser H, Glickson JD, Schuster SJ, Ptasznik A, Wasik MA

Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019 Jul;25(7):1387-1394 Epub 2019 Mar 30; Authors: Derenzini E, Risso A, Ruella M, Spatola T, Milone G, Pioltelli P, Iori AP, Santarone S, Bosi A, Rambaldi A, Bacigalupo AP, Arcese W, Tarella C

Emerging Cellular Therapies for Cancer.
Annual review of immunology. 2019 Apr 26;37:145-171 Epub 2018 Dec 10; Authors: Guedan S, Ruella M, June CH

Novel Immunotherapies for T Cell Lymphoma and Leukemia.
Current hematologic malignancy reports. 2018 Dec;13(6):494-506; Authors: Ghione P, Moskowitz AJ, De Paola NEK, Horwitz SM, Ruella M

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.
Nature medicine. 2018 Oct;24(10):1499-1503 Epub 2018 Oct 1; Authors: Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ

Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.
Leukemia & lymphoma. 2018 Sep;59(9):2040-2055 Epub 2017 Nov 22; Authors: Rotolo A, Karadimitris A, Ruella M

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).
Journal for immunotherapy of cancer. 2018 Jul 11;6(1):69; Authors: Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I

Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans.
Molecular therapy : the journal of the American Society of Gene Therapy. 2018 Jun 6;26(6):1401-1403 Epub 2018 May 19; Authors: Ruella M, June CH

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
Cell. 2018 May 31;173(6):1439-1453.e19; Authors: Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S

Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.
Oncotarget. 2018 May 25;9(40):25764-25780; Authors: Bu DX, Singh R, Choi EE, Ruella M, Nunez-Cruz S, Mansfield KG, Bennett P, Barton N, Wu Q, Zhang J, Wang Y, Wei L, Cogan S, Ezell T, Joshi S, Latimer KJ, Granda B, Tschantz WR, Young RM, Huet HA, Richardson CJ, Milone MC

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
JCI insight. 2018 Apr 5;3(7); Authors: Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer.
Current hematologic malignancy reports. 2017 Dec;12(6):522-529; Authors: Singh N, Shi J, June CH, Ruella M

Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2017 Dec;31(6):473-481; Authors: Ruella M, Kenderian SS

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.
Cancer discovery. 2017 Oct;7(10):1154-1167 Epub 2017 Jun 2; Authors: Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S

Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
Blood. 2017 Apr 27;129(17):2395-2407 Epub 2017 Feb 28; Authors: Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S

Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.
Hematology. American Society of Hematology. Education Program. 2016 Dec 2;2016(1):432-436; Authors: Ruella M, Soubeyran P

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.
The Journal of clinical investigation. 2016 Oct 3;126(10):3814-3826 Epub 2016 Aug 29; Authors: Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, Gill S

Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.
Current hematologic malignancy reports. 2016 Oct;11(5):368-84; Authors: Ruella M, June CH

Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies.
Computational and structural biotechnology journal. 2016;14:357-362 Epub 2016 Sep 28; Authors: Ruella M, Maus MV

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Jun 1;22(11):2684-96 Epub 2016 Jan 27; Authors: Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA

Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
International journal of radiation oncology, biology, physics. 2016 Mar 15;94(4):783-91 Epub 2015 Dec 17; Authors: Ruella M, Filippi AR, Bruna R, Di Russo A, Magni M, Caracciolo D, Passera R, Matteucci P, Di Nicola M, Corradini P, Parvis G, Gini G, Olivieri A, Ladetto M, Ricardi U, Tarella C, Devizzi L

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Blood. 2016 Mar 3;127(9):1117-27 Epub 2016 Jan 26; Authors: Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV

Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma.
Annals of translational medicine. 2016 Jan;4(1):13; Authors: Ruella M, Levine BL

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.
Cancer discovery. 2015 Dec;5(12):1282-95 Epub 2015 Oct 29; Authors: Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A

How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.
Expert opinion on biological therapy. 2015 Jun;15(6):761-6 Epub 2015 Feb 2; Authors: Ruella M, Gill S

Chimeric antigen receptor T-cell therapy to target hematologic malignancies.
Cancer research. 2014 Nov 15;74(22):6383-9 Epub 2014 Nov 4; Authors: Kenderian SS, Ruella M, Gill S, Kalos M

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.
British journal of haematology. 2014 Nov;167(4):541-6 Epub 2014 Aug 16; Authors: Lussana F, Carobbio A, Randi ML, Elena C, Rumi E, Finazzi G, Bertozzi I, Pieri L, Ruggeri M, Palandri F, Polverelli N, Elli E, Tieghi A, Iurlo A, Ruella M, Cazzola M, Rambaldi A, Vannucchi AM, Barbui T

Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival.
PloS one. 2014;9(9):e106745 Epub 2014 Sep 25; Authors: Tarella C, Gueli A, Delaini F, Rossi A, Barbui AM, Gritti G, Boschini C, Caracciolo D, Bruna R, Ruella M, Gottardi D, Passera R, Rambaldi A

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
Blood. 2014 Apr 10;123(15):2343-54 Epub 2014 Mar 4; Authors: Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M

Pregnancy complications predict thrombotic events in young women with essential thrombocythemia.
American journal of hematology. 2014 Mar;89(3):306-9 Epub 2014 Feb 19; Authors: Randi ML, Bertozzi I, Rumi E, Elena C, Finazzi G, Vianelli N, Polverelli N, Ruggeri M, Vannucchi AM, Antonioli E, Lussana F, Tieghi A, Iurlo A, Elli E, Ruella M, Fabris F, Cazzola M, Barbui T

Adoptive immunotherapy for cancer.
Immunological reviews. 2014 Jan;257(1):14-38; Authors: Ruella M, Kalos M

Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.
Annals of hematology. 2013 Nov;92(11):1503-11 Epub 2013 Jun 5; Authors: Ferrero S, Monitillo L, Mantoan B, Barbero D, Genuardi E, Barbiero S, Bernocco E, Caracciolo D, Ruella M, Drandi D, Zanni M, Renna F, Lobetti Bodoni C, Gueli A, Passera R, Musto P, Boccadoro M, Tarella C, Ladetto M

Multiple courses of G-CSF in patients with decompensated cirrhosis: consistent mobilization of immature cells expressing hepatocyte markers and exploratory clinical evaluation.
Hepatology international. 2013 Oct;7(4):1075-83 Epub 2013 Oct 11; Authors: Gaia S, Olivero A, Smedile A, Ruella M, Abate ML, Fadda M, Rolle E, Omedè P, Bondesan P, Passera R, Risso A, Aragno M, Marzano A, Ciancio A, Rizzetto M, Tarella C

Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Aug 10;31(23):2974-6 Epub 2013 Jul 15; Authors: Devizzi L, Guidetti A, Seregni E, Passera R, Maccauro M, Magni M, Testi A, Di Nicola M, Tarella C, Matteucci P, Viviani S, Ruella M, Carlo-Stella C, Chiesa C, Cox MC, Bombardieri E, Gianni AM

Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Experimental hematology. 2013 Jul;41(7):627-34 Epub 2013 Mar 28; Authors: Ruella M, Salmoiraghi S, Risso A, Carobbio A, Buttiglieri S, Spatola T, Sivera P, Ricca I, Barbui T, Tarella C, Rambaldi A

A short course of granulocyte-colony-stimulating factor to accelerate wound repair in patients undergoing surgery for sacrococcygeal pilonidal cyst: proof of concept.
Cytotherapy. 2012 Oct;14(9):1101-9 Epub 2012 Jul 12; Authors: Baldelli CM, Ruella M, Scuderi S, Monni M, Passera R, Omedè P, Tarella C

Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2012 Jun;23(4):331-4; Authors: Sivera P, Ruella M, Gueli A, Hu H, Wade M, Tarella C

The aging effect of chemotherapy on cultured human mesenchymal stem cells.
Experimental hematology. 2011 Dec;39(12):1171-81 Epub 2011 Aug 22; Authors: Buttiglieri S, Ruella M, Risso A, Spatola T, Silengo L, Avvedimento EV, Tarella C

Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
Cancer. 2011 Nov 15;117(22):5074-84 Epub 2011 May 12; Authors: Guidetti A, Carlo-Stella C, Ruella M, Miceli R, Devizzi L, Locatelli SL, Giacomini A, Testi A, Buttiglieri S, Risso A, Mariani L, Di Nicola M, Passera R, Tarella C, Gianni AM